AACR 2026: Lung Cancer Immunotherapy Response Predicted by Pathomics AI Model
Path-IO accurately stratified immunotherapy outcomes for patients with metastatic non-small cell lung cancer (NSCLC). The model is validated across international real-world cohorts and a Phase III randomized clinical trial. The post AACR 2026: Lung Cancer Immunotherapy Response Predicted by Pathomics AI Model appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Source
Read the full article at Genengnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.